The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

This once-daily pill offers a convenient, alternative to blockbuster drugs like ... even more weight. By comparison, Lilly’s injectable Zepbound achieved 15.3% to 36.2% weight loss in a 72 ...

Find out about kids' average weight and height from birth to 8 years old – and learn what your child's growth percentile ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Coincidentally, these drugs are also favoring weight loss ... Full data will be reported soon from the SURMOUNT-5 trial on comparison of weight loss with tirzepatide vs semaglutide 2.4 mg ...

The existing treatments for weight loss have ... on a potential drug to boost calorie expenditure. The scale of the deal-making remains relatively small, at this stage, in comparison to the ...

For comparison, people treated with placebo ... today after it reported phase 3 results for oral diabetes and weight-loss drug orforglipron.

Abbott's growth potential with GLP-1 tailwinds, robust FCF, and dividend growth. Read more on how ABT navigates tariffs while ...

Tuna is awash in helpful nutrients like iron and omega-3 fatty acids—not to mention delicious in sushi, salads, and ...

Roche has pledged to build a giant weight-loss drug factory in the US. The plans form part of a $50bn (£37bn) pledge aimed at ...

Made in the USA, a new daily oral weight-loss pill from Eli Lilly won't require cold storage and is expected to hit markets ...

Eli Lilly's Mounjaro (Tirzepatide), a dual GIP and GLP-1 receptor agonist, has launched in India, generating buzz as a weight loss drug similar to Ozempic. Gastroenterologist Dr. Pal Manickam ...